(⊙ω⊙)♡ try KnowYourSong.com largest music lyrics database

Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC

Say and pronounce Dr. Spigel On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  Dr. Spigel on Pembrolizumab/Chemo Combo in First-Line NSCLC   Dr. West on FDA Approval of Brigatinib in ALK+ NSCLC   Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC   Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC   FDA Approval of Brigatinib for ALK+ NSCLC   FDA Approval of Atezolizumab for NSCLC   FDA Approval: Frontline Ceritinib for ALK+ NSCLC   Checkpoint Inhibitors for Relapsed or Refractory NSCLC   Combined Immunotherapy and Chemotherapy for NSCLC   Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval   Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL   Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer   Dr. Bendell on FDA Approval of Regorafenib in Liver Cancer   Dr. Al-Kali on FDA Approval of Enasidenib in AML   Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma   Review on 2016 FDA Approvals, Halt on AML Trials, and More   Breakthrough In Leukemia Treatment   New drug trial heals dogs of arthritis   Clarence-based company could become first to sell very low nicotine cigarette   Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Thera for ALK+ NSCLC   Extended Cut: Should the Terminally Ill Have the Right to Try, Non FDA Approved Drugs?   Durvalumab FDA Approval for Bladder Cancer   The FDA Approval of Atezolizumab in Bladder Cancer   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   New cancer treatment offers patients hope   Novartis Metastatic Breast Cancer Treatment   Cancer Advance of the Year, FDA Approval for CINV, Breakthrough Designation in TNBC, And More   FDA Approval in AML, Priority Review Designation in NSCLC, and More   FDA Approval in MZL, Delay in Immunotherapy Combos in NSCLC, and 2017 GI Symposium Highlights   FDA Approval in CLL, Recommendation in NSCLC, Missed Endpoint in GBM Study, and More   FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More   FDA Approval in Lung Cancer, Priority Reviews in HCC and NHL, and an ODAC Recommendation   21st Century Cures Act Passes and 2016 Highlights from SABCS and WCLC   Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC   Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC   Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast Cancer   Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer   Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer   Dr. Erba on the FDA Approval of CPX-351 in AML   Buffalo first city in U.S. to use new ALS drug   FDA Approval of Durvalumab for Bladder Cancer   Nivolumab Lung Cancer Approval Expanded, Abemaciclib Granted Breakthrough Status, and More   How Does The FDA Approve New Drugs?   Dr. Chandra Belani on Atezolizumab in NSCLC   Dr. Drilon on RET Rearrangements in NSCLC   UK's Dr. Thomas Whayne on PCSK9 inhibitors   Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer   Reid: Senate Must Act To End Life-Saving Drug Shortages   Vivek Ramaswamy On Getting An Alzheimer's Drug Approved | Forbes   Expert: New Women's Sex Drug 'A Step Forward'   Dr. Blackwell on Neratinib in HER2+ Breast Cancer   FDA Approves Frontline Nivolumab for Advanced Melanoma   Local man with ALS disappointed with FDA   'Our Cancer Drug Is For Rich Westerners, Not Poor Indians'   Vivek Ramaswamy On Getting An Alzheimer's Drug Approved | Forbes   Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC   Treatment for primary progressive Multiple Sclerosis   FDA Approval Sought in ALL, Early 2017 GU Symposium Highlights, and New HHS Secretary Confirmed   FDA Approval in ALL, Priority Reviews in CML and Breast Cancer, and More   Is This ‘Little Pink Pill’ The Viagra For Women? | NBC Nightly News   Dr. Reidy-Lagunes on FDA Approval of Telotristat Epitrate for Carcinoid Syndrome   A Roadmap for Medical Devices: From Innovative Ideas to the U.S. Market   FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More   FDA Approval in AML, NDA Submitted in Myeloma, Clinical Hold on CAR T-cell Therapy Trials, and More   FDA Approvals in CRC, Blood Cancer Detection Diagnostic, and Alopecia, and More   Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC   Dr. Garon on Future of Immunotherapy in NSCLC   FDA Approvals in Breast Cancer and Melanoma, Disappointing Results in HNSCC, and More   Big Banks and Big Pharma Just Scored A Huge Payday From The Dysfunctional FDA   FDA Approval in Myeloma, Priority Review in ALL, and 2017 GU Cancers Symposium Highlights   One In Three Drugs Still Offer Safety Concerns After Passing FDA Approval   FDA Approvals in CRC, Blood Diagnostic, and Alopecia, and More   The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

Popular Today